$422.53 0.00 (0.00%)

United Therapeutics Corp (UTHR)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. Founded in 1996, the company specializes in treatments for pulmonary arterial hypertension and related conditions, leveraging biotechnological advances to improve patient outcomes.

🚫 United Therapeutics Corp does not pay dividends

Company News

Artificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034
GlobeNewswire Inc. • Towards Healthcare • October 17, 2025

The artificial lung market is projected to grow from $2.78 billion in 2025 to $7.05 billion by 2034, with a 10.84% CAGR. North America dominates the market, driven by rising respiratory disease prevalence and technological advancements in medical devices.

3 High-Growth Stocks Poised to Extend Gains Into Year-End
Investing.com • Damian Nowiszewski • September 11, 2025

Despite ongoing global tensions, the stock market showed resilience during the holiday season, with the S&P 500 and Nasdaq rising. Three high-growth stocks - PDD Holdings, Alphabet, and United Therapeutics - demonstrated strong performance and potential for continued gains through year-end.

MannKind (MNKD) Q2 Revenue Rises 6%
The Motley Fool • Jesterai • August 6, 2025

MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
Benzinga • Mohit Manghnani • June 15, 2025

Several large-cap stocks, including AppLovin, Chewy, and Carvana, were among the top losers last week. The declines were attributed to factors such as weak earnings guidance, lower-than-expected sales outlook, and bearish options activity.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Zacks Investment Research • Zacks Investment Research • August 6, 2024

The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeut...